BioPharma Reporter
JULY 11, 2024
Amid a period of clinical holds and legal tangles, the US antibody specialist CytoDyn has reached a settlement to resolve legal disputes with its former contract research organization (CRO) Amarex Clinical Research.
pharmaphorum
JANUARY 25, 2021
GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lung cancer drug last week. The post GSK suffers another R&D setback, axing ulcerative colitis drug trial appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
APRIL 1, 2021
One of the common research approaches to treating brain diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) is using antibodies designed to clear the accumulated misfolded proteins implicated in the diseases. To date, these drug trials have not been particularly successful at i.
Advarra
MARCH 21, 2023
These products will require clinical trial data to get to market, but with significantly fewer participants required as compared to a drug trial. Class 3: Applied to products with the highest risk, or to Class 2 products that are the first in their category. Think of the intent or purpose for the intended use (e.g.,
The Pharma Data
NOVEMBER 10, 2020
We wanted a tau antibody that would bind to the expressed forms of tau, so we developed a very specific assay,” Dage said. The plasma assay elements include: Capture – a biotin-labeled anti-phosphor-thr217-tau antibody. Detection – a ruthenium-labeled isoform-specific anti-tau antibody.
XTalks
APRIL 26, 2021
Given the success of Oxford’s Phase II trial, the study investigators are now gearing up for a Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children aged 5 to 36 months across four countries in Africa. Developing an efficacious vaccine against malaria has been a huge challenge.
Pharmaceutical Technology
APRIL 27, 2023
LNPs are an adaptable, modular technology and when combined with microfluidic mixing, have the potential to accelerate development and commercialisation timelines and provide drug developers with an early foothold into a largely untapped market. There was a lot of cynicism and questions, like: ‘Why would you want to use single use?
Expert insights. Personalized for you.
98 
Let's personalize your content